45

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette Å, Rasmussen F, Salo J, Vaage S, Varenhorst E and the SPCG-5 Study Group.

Scand J Urol Nephrol. 2008

SPCG-5

Abstract

44

Experiences of randomization: Interviews with patients and clinicians in the SPCG-IV trial

Bill-Axelson A, Christensson A, Carlsson M, Norlén BJ, Holmberg L

Scand J Urol Nephrol. 2008

SPCG-4

Abstract

43

The early prostate cancer program: bicalutamide in nonmetastatic prostate cancer

Iversen P, Roder MA

Expert Rev Anticancer Ther 2008

Abstract

42

Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival

Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, Christensen IJ

Clin Cancer Res. 2007

SPCG-5

Abstract

41

Prostate-specifik antigen levels as a predictor of lethal prostate cancer

Fall K, Garmo H, Andrén O, Bill-Axelson, Adolfsson J, Adami H-O,Johansson J-E, Holmberg L

J Natl Cancer Inst. 2007

SPCG-4

Abstract

40

Prognostic markers under watchful waiting and radical prostatectomy

Holmberg L, bill-Axelson A, Garmo H, Palmgren J, Norlén HB, Adami H-O, Johansson J-E

Hematol Oncol Clin North Am. 2006

SPCG-4

Abstract

39

Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?

Warren KS, Chodak GW, See WA, Iversen P, McLeod D, Wirth M, Morris C, Armstrong J

Journal of Urology 2006

Abstract

38

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

Iversen P, Johansson J-E, Lodding P, Kylmälä T, Lundmo P, Klarskov P, Tammela T, Tasdemir I, Morris T, Amstrong J

Scand J Urol Nephrol 2006

SPCG-6

Abstract

37

Prognostic value of serum PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma

Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P

The Prostate 2006

Abstract

36

The third analysis of the bicalutamide early prostate cancer programme

Iversen P

British Journal of Urology International 2006

Abstract